drugset / Trial / NCT00006455

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

NCT00006455

Phase 3 Completed 885 enrolled Gustave Roussy, Cancer Campus, Grand Paris
RandomizedSingle-groupTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for treating anaplastic large cell lymphoma. PURPOSE: This randomized phase III trial is studying several different regimens of combination chemotherapy to compare how well they work in treating children with anaplastic large cell lymphoma.

Timeline

Start
1999-11-26
Primary completion
2009-01-12
Completion
2020-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 1 g Intrathecal
Subject Methotrexate Small molecule 3 g Intrathecal
Subject Vinblastine Small molecule 6 mg/m2
Background Cyclophosphamide Other / unclassified Intravenous
Background Cytarabine Small molecule Intravenous
Background Dexamethasone Small molecule Intravenous
Background Doxorubicin Other / unclassified Intravenous
Background Etoposide Small molecule Intravenous
Background Hydrocortisone Other / unclassified Intrathecal
Background Ifosfamide Small molecule Intravenous
Background Leucovorin Small molecule Intravenous

Indications